ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,708.60
3.40 (0.20%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.40 0.20% 1,708.60 1,708.60 1,708.80 1,713.00 1,699.40 1,701.60 11,522,668 16:29:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.27 70.34B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,705.20p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £70.34 billion. Gsk has a price to earnings ratio (PE ratio) of 14.27.

Gsk Share Discussion Threads

Showing 14126 to 14149 of 33075 messages
Chat Pages: Latest  567  566  565  564  563  562  561  560  559  558  557  556  Older
DateSubjectAuthorDiscuss
26/4/2017
22:30
NY, I'm guessing you are holding a few by now!.


Michael mentioned how many GSK he holds recently, think it was over 30,000 shares,
nerves of steel, or rich, may be both ).

essentialinvestor
26/4/2017
22:07
Now when we compare the intrinsic value of £17.57 to the current share price of £15.99 we see GlaxoSmithKline (LSE:GSK) is a touch undervalued at a 9% discount to what it is available for right now.
ny boy
26/4/2017
19:58
'GlaxoSmithKline: Good News, 2016's Positive Momentum Continues'
philanderer
26/4/2017
18:54
This is the CEO on today's Q&A (transcript from Seeking Alpha).

.."just to reiterate, beyond any kind of update on restructuring programs, it's something that Simon and I are discussing a lot and with the leadership team, a much more disciplined focus on general running costs and cash consciousness across the whole company...'



So scope for some margin improvement imv, notice Emma's phrase ... a much more disciplined focus.

essentialinvestor
26/4/2017
18:38
Added more at 1572, a bit too early! Will add more as an when funds available under 16 quid.
spoole5
26/4/2017
17:55
Will add more tomorrow if the market lets me, great solid blue chip company
ny boy
26/4/2017
16:05
I hope this starts to move higher! Great set of results solid company
mj19
26/4/2017
15:57
Michael, good call on the 2017 dividend, expected a
rebasing under Emma to 50-55 giving more flexibility, the sector average yield looks around 3%.

Operational efficiencies route they look to be taking.

essentialinvestor
26/4/2017
15:26
I think its down on lack of guidance on revenue given Advair competition and how it will impact.

Great set of results. Who wouldn't want to own a large cap, high dividend paying future growth champion with a new ceo (likely cost cutting exercise coming) with its revenues from 3 diversified business income streams - one of which VIIV is truly outstanding!

Anyways I will continue to hold and add with pf's divi income if this price persists.

nimbo1
26/4/2017
15:21
Michael, just fwiw, there was an element of managing expectations on the call, as an example.. we have a lot of work to do on the early stage pipeline etc,
that was underlined.

Can understand why, if the new CEO says something along the lines of..
GSK is in fantastic shape, nothing to improve etc, it just sets her tenure
up for future disappointment.

And improvements can be made on productivity, most would agree on that.

Emma's presentation style is also very understated in comparison to Andrew,
Andrew was a cheerleader type approach.

essentialinvestor
26/4/2017
15:08
Almost 2% drop on stunning results. What does it take for this share to go UP?...... bizarre ....;0)
tradermichael
26/4/2017
14:50
NY, did say there was a big move coming on the update!.

It's mild % move at this stage, might be a sell in to the close.

essentialinvestor
26/4/2017
14:49
Buy those lovely dips Sir!
ny boy
26/4/2017
13:29
Just listening to the Q&A - keeping the current group structure ..under
regular review.
Although see benefits in the current combination.



Also looking for additional NVS transaction integration costs, beyond those already outlined.

A new wider restructuring programme come July's Q update (apologies said June earlier)
on the cards imv, looks like they will be laser focussed on costs.

essentialinvestor
26/4/2017
13:26
MJ , just a bit of 'sell on the news'. Should recover I would have thought.



'The world's first malaria vaccine is coming to Ghana, Kenya, and Malawi'

philanderer
26/4/2017
12:56
Guys we seem to be heading down today, I thought the results were good on all fronts
mj19
26/4/2017
12:47
Essential
Thanks, got caught going down the hill towards Station, just got a telling off.

montyhedge
26/4/2017
12:38
Hi phil, respiratory looks very encouraging to me.

This is before closed triple approval.

Would prefer a lower dividend to give a bit more flexibility,
but appreciate that is very much a minority view!.

essentialinvestor
26/4/2017
12:37
Afternoon EI , no shocks, much as expected . No broker upgrades ;-)
philanderer
26/4/2017
12:34
phil, looks like Emma will make a more detailed statement on
GSK's future direction on the June update.


Just reading her wording, there may be a slight hint of some strategic
review. An eventual spin off in consumer healrhcare would make sense. Pharma
and vaccines better together. Just IMV only.

essentialinvestor
26/4/2017
12:22
Sharecast:

...........Later on a conference call, said she was committed to the group's three-pillar structure, confirming there were no plans to spin-off the consumer healthcare division.

She also said she wanted to renewed focus on the commercialisation of GSK's research and development in order to improve the rate of return.

Among the GSK pipeline saw new product sales of £1.4bn, up 72% and on track to deliver £6bn in 2018.

Recently published studies has demonstrated encouraging data for Nucala for severe asthma, a combination therapy for HIV, for shingles vaccine Shingrix, while former prescription drug Flonase Sensimist for allergy relief was launched as an over-the-counter product in the US, the second such switch in three years.

philanderer
26/4/2017
12:15
'Sales at GlaxoSmithKline jump 19pc as new boss settles in'


GlaxoSmithKline has beaten analyst expectations by increasing its sales 19pc in the first quarter under new boss Emma Walmsley.

Sales at the pharmaceutical giant hit £7.4bn in the three months to March 31, up from £6.2bn a year previously and higher than the £7.25bn pencilled in by analysts.

However, the company warned that the emergence of rival drugs to its Advair asthma treatment meant it could not accurately forecast its performance for the full year.

The firm has repeatedly warned that sales could be hit if a rival generic drug was given the go-ahead by regulators.

Although an application by rival Mylan to market a copy of the drug was rejected by the US Food and Drug Administration last month, Israeli drugmaker Teva unveiled a new product to rival Advair last week.

On Wednesday, GSK reiterated previous guidance that said that if no generic version of Advair is introduced to the US market, then its earnings would grow by between 5pc and 7pc this year. But if one is introduced during 2017, earnings would be flat or could decline, it warned.

philanderer
26/4/2017
11:29
Hailstones in Weybridge atm monty, take it you are not out on the golf course!.

Police doing a lot of speed checks on local roads just to make you aware M.

essentialinvestor
26/4/2017
11:27
Seem ok, my problem with GSK never increases dividend 80p again this year. So in fact its like having a bond. I rather have the GSK bond.
montyhedge
Chat Pages: Latest  567  566  565  564  563  562  561  560  559  558  557  556  Older

Your Recent History

Delayed Upgrade Clock